Therapeutic effect of artemisinin on lupus nephritis mice and its mechanisms

Acta Biochimica et Biophysica Sinica

Volumn 42, Issue 12, 2010, Pages 916-923

  Wu, Xili ^a   Zhang, Wanggang ^b   Shi, Xingmin ^a   An, Peng ^a   Sun, Wansen ^a   Wang, Zhu ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

artemisinin; lupus nephritis mice; NF B; NF Bp65 protein; TGF 1 mRNA

Indexed keywords

ANTIINFECTIVE AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE; INTERLEUKIN 6; MESSENGER RNA; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BLOOD; C57BL MOUSE; DBA MOUSE; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; LUPUS ERYTHEMATOSUS NEPHRITIS; METABOLISM; MOUSE; PATHOLOGY; PROTEINURIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; URINE;

ANIMALS; ANTI-INFECTIVE AGENTS; ARTEMISININS; DOWN-REGULATION; FEMALE; INTERLEUKIN-6; LUPUS NEPHRITIS; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; PROTEINURIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 78649642749     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmq101     Document Type: Article

References (30)

1. Wang J, Zhang B, Guo Y, Li G, Xie Q, Zhu B and Gao J, et al. Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C. Pharmacology 2008, 82: 148-155.
2. Wang J, Guo Y, Zhang BC, Chen ZT and Gao JF. Induction of apoptosis and inhibition of cell migration and tube-like formation by dihydroartemi-sinin in murine lymphatic endothelial cells. Pharmacology 2007, 80: 207-218.
3. Wang ZJ, Qiu J, Guo TB, Liu A, Wang Y, Li Y and Zhang JZ. Anti-inflammatory properties and regulatory mechanism of a novel derivative of artemisinin in experimental autoimmune encephalomyelitis. J Immunol 2007, 179: 5958-5965.
4. Aldieri E, Atragene D, Bergandi L, Riganti C, Costamagna C, Bosia A and Ghigo D. Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation. FEBS Lett 2003, 552: 141-144.
5. Xu DX, Zhang WD, Dai CS, Yu XS, Yu GR and Zhao ZS. Observation of artemisinin on the experimental lung prevention and therapy. Medic Res 1998, 27: 43-44.
6. Sadava D, Phillips T, Lin C and Kane SE. Transferrin overcomes drug resistance to artemisinin in human small cell lung carcinoma cells. Cancer Lett 2002, 179: 151-156. (Pubitemid 34215106)
7. Singh NP and Lai HC. Artemisinin induces apoptosis in human cancer cells. Anticancer Res 2004, 24: 2277-2280.
8. Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, Vakar-Lopez F and Goodlett DR, et al. Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs 2010, 21: 423-432.
9. Michaelis M, Kleinschmidt MC, Barth S, Rothweiler F, Geiler J, Breitling R and Mayer B, et al. Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. Biochem Pharmacol 2010, 79: 130-136.
10. Chen T, Li M, Zhang R and Wang H. Dihydroartemisinin induces apoptosis and sensitizeshuman ovarian cancer cells to carboplatin therapy. J Cell Mol Med 2009, 13: 1358-1370.
11. D'Agati V and Schmidt AM. RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol 2010, 6: 352-360.
12. Lu CS, Ye RG, Sun L, Yang NS, Li HQ and Liu GX. Survival probability and predictors of death in patients with lupus nephritis. Zhonghua Nei Ke Za Zhi 1998, 37: 250-253.
13. Bruijn JA, van Elven EH, Hogendoorn PC, Corver WE, Hoedemaeker PJ and Fleuren GJ. Murine chronic graft-versus-host disease as a model for lupus nephritis. Am J Pathol 1988, 130: 639-641.
14. Zheng L, Sinniah R and Hsu SI. Pathogenic role of NF-kB activation in tubulointerstitial inflammatory lesions in human lupus nephritis. J Histochem Cytochem 2008, 56: 517-529.
15. Sabry A, Elbasyouni SR, Sheashaa HA, Alhusseini AA, Mahmoud K, George SK and Kaleek EA. Correlation between levels of TNF-a and IL-6 and hematological involvement in SLE Egyptian patients with lupus nephritis. Int Urol Nephrol 2006, 38: 731-737.
16. Robak E, Sysa-Jdrzejowska A, Robak T, Stpiefi H, Woniacka A and Waszczykowsk E. Tumor necrosis factor alpha (TNF-a), interleukin-6 (IL-6) and their soluble receptors (sTNF-a-Rp55 and slL-6R) serum levels in systemic lupus erythematodes. Mediators Inflamm 1996, 5: 435-441.
17. Yang CW, Yu CC, Ko YC and Huang CC. Aminoguanidine reduces glo-merular inducible nitric oxide synthase (iNOS) and transforming growth factor-b1 (TGF-b1) mRNA expression and diminishes glomerulosclerosis in NZB/W F1 mice. Clin Exp Immunol 1998, 113: 258-264.
18. Zheng L, Sinniah R and Hsu SI. In situ glomerular expression of activated NF-kappaB in human lupus nephritis and other non-proliferative protein uric glomerulopathy. Virchows Archiv 2006, 448: 172-183.
19. Zhou P, Chen XR, Li SY and Tu SQ. Expression of transforming growth factor b genes in kidneys of BXSB lupus mice. Zhongguo Pi Fu Xing Bing Xue Za Zhi 1999, 13: 77-78.
20. Brown G and Thiele DL. T-cell activation and differentiation are regulated by TNF during murine DBA/2-B6D2F1 intestinal graft-versus-host disease. J Clin Immunol 2000, 20: 379-388.
21. Meyers CM, Tomaszewski JE, Glass JD and Chen CW. The nephritogenic T cell response in murine chronic graft-versus-host disease. J Immunol 1998, 161: 5321-5330.
22. Werle E, Blazek M and Fiehn W. The clinical significance of measuring different anti-dsDNA antibodies by using the Farr assay, an enzyme immunoassay and a Crithidia luciliae immunofluorescence test. Lupus 1992, 6: 369-377.
23. Kim C, Siminovitch KA and Ochi A. Reduction of lupus nephritis in MRL/Ipr mice by a bacterial superantigen treatment. J Exp Med 1991, 174: 1431-1437.
24. Chuang YH, Chuang WL, Huang SP, Liu CK and Huang CH. Inhibition of nuclear factor-kB (NF-kappaB) activation attenuates ureteric damage in obstructive uropathy. Pharmacol Res 2009, 60: 347-357.
25. He W, Liu K and Ding H. The relationship between transforming growth factor b1 expression and cold ischemia injury of rat donor kidney. Exp Mol Pathol 2010, 88: 206-209.
26. Rangan GK, Wang Y, Tay YC and Harris DC. Inhibition of NF-kB activation with antioxidants is correlated with reduced cytokine transcription in PTC. Am J Physiol 1999, 277: F779-F789.
27. Philip S, Bulbule A and Kundu GC. Matrix metalloproteinase-2: mechanism and regulation of NF-kB-mediated activation and its role in cell moti-lity and ECM-invasion. Glycocorj J 2004, 21: 429-441.
28. Guijarro C, Kim Y, Kasiske BL, Massy ZA, O'Donnell MP, Kashtan CE and Keane WF. Central role of the trascription factor NF-kB in mesangial cell production of chemokines. Contrib Nephrol 1997, 120: 210-218.
29. Rangan GK, Wang Y, Tay YC and Harris DC. Inhibition of nuclear factor-kB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int 1999, 56: 118-134.
30. Rangan GK, Wang Y, Tay YC and Harris DC. Cytokine gene expression in adriamycin nephropathy: effects of antioxidant nuclear factor kB inhibitors in established disease. Nephron 2000, 86: 482-490.